首页> 外文期刊>Molecular cancer research: MCR >Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer
【24h】

Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer

机译:结合外泌体GPC1,CD82和血清CA19-9作为多重靶标:用于诊断胰腺癌的特定,敏感和可重复的检测面板

获取原文
获取原文并翻译 | 示例
           

摘要

Pancreatic cancer is a highly lethal malignancy with poor prognosis due to the lack of early symptoms and resultant late diagnosis. Thus, it is extremely urgent to establish a simple and effective method for the early diagnosis of pancreatic cancer. Although some studies have provided positive evidence for the use of exosomal surface protein glypican-1 (GPC1) as a biomarker for early screening, its clinical application is still controversial. Here, we systematically verified the role of exosomal GPC1 as a potential screening biomarker. First, bottleneck problems of a stable detection method and an identification standard were systematically studied, and a Python-based standardized data processing method was established to analyze exosomal GPC1 expression. Second, a detection panel consisting of exosomal GPC1, exosomal cluster of differentiation 82 (CD82), and serum carbohydrate antigen 19-9 (CA19-9) was employed for pancreatic cancer detection. This panel exhibited excellent diagnostic results (AUC = 0.942) and could effectively distinguish healthy people from patients with pancreatic cancer (P value threshold = 0.2282) and patients with pancreatitis from patients with pancreatic cancer ( P value threshold = 0.5467).
机译:由于缺乏早期症状和晚期诊断,胰腺癌是一种高度致命的恶性肿瘤,其预后差。因此,建立一种简单有效的胰腺癌早期诊断方法是非常迫切的。虽然一些研究已经为使用外泌体表面蛋白糖尿病-1(GPC1)提供了阳性证据作为早期筛查的生物标志物,但其临床应用仍然存在争议。在这里,我们系统地验证了外泌体GPC1作为潜在筛选生物标志物的作用。首先,系统地研究了稳定检测方法和识别标准的瓶颈问题,并建立了一种基于蟒蛇的标准化数据处理方法,以分析外泌体GPC1表达。其次,采用由外泌体GPC1,外泌体分化82(CD82)和血清碳水化合物抗原19-9(CA19-9)组成的检测面板进行胰腺癌检测。该面板表现出优异的诊断结果(AUC = 0.942),可有效地区分胰腺癌(P值阈值= 0.2282)的健康人员,胰腺癌患者(P值阈值= 0.5467)。

著录项

  • 来源
    《Molecular cancer research: MCR》 |2020年第2期|共11页
  • 作者单位

    Xi An Jiao Tong Univ Hanzhong Hosp 3201 Dept Ontol Surg Hanzhong Peoples R China;

    Hebei Gen Hosp Dept Pharm Shijiazhuang Hebei Peoples R China;

    Shanghai Biotecan Pharmaceut Co Ltd Shanghai Zhangjiang Inst Med Innovat Shanghai Peoples R China;

    Shanghai Jiao Tong Univ Dept Gen Surg Affiliated Hosp 6 Shanghai Peoples R China;

    Shanghai Jiao Tong Univ Dept Gen Surg Affiliated Hosp 6 Shanghai Peoples R China;

    Linfen Peoples Hosp Dept Gen Surg Linfen Shanxi Peoples R China;

    Hebei Gen Hosp Dept Gen Surg Shijiazhuang Hebei Peoples R China;

    Xi An Jiao Tong Univ Hanzhong Hosp 3201 Dept Orthoped Hanzhong Peoples R China;

    Shanghai Biotecan Pharmaceut Co Ltd Shanghai Zhangjiang Inst Med Innovat Shanghai Peoples R China;

    Shanghai Biotecan Pharmaceut Co Ltd Shanghai Zhangjiang Inst Med Innovat Shanghai Peoples R China;

    Shanghai Biotecan Pharmaceut Co Ltd Shanghai Zhangjiang Inst Med Innovat Shanghai Peoples R China;

    Shanghai Jiao Tong Univ Med X Res Inst Sch Biomed Engn Shanghai Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号